Skip to main content
OTCMKTS:MLLCF

Molecular Partners Stock Forecast, Price & News

$22.48
+0.09 (+0.38 %)
(As of 05/14/2021 03:05 PM ET)
Add
Compare
Today's Range
$22.28
▼
$23.00
50-Day Range
$22.40
▼
$26.25
52-Week Range
$16.00
▼
$33.00
Volume1,451 shs
Average Volume4,923 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MLLCF News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.


Molecular Partners logo

About Molecular Partners

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.

Headlines

Molecular Partners COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants In Vitro
Molecular Partners' COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants In Vitro
May 6, 2021 |  finance.yahoo.com
Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline
Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline
May 4, 2021 |  finance.yahoo.com
Molecular Partners (OTCMKTS:MLLCF) Trading Down 0.7%
Molecular Partners (OTCMKTS:MLLCF) Trading Down 0.7%
April 27, 2021 |  americanbankingnews.com
Molecular Partners AG: Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States
Molecular Partners AG: Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States
April 23, 2021 |  finanznachrichten.de
Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States
Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States
April 23, 2021 |  benzinga.com
Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli Elected New Board Members
Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli Elected New Board Members
April 21, 2021 |  finance.yahoo.com
Avantor® to Acquire Ritter GmbH and its Affiliates; Expands Proprietary Offering for Diagnostic and Drug Discovery Workflows
Avantor® to Acquire Ritter GmbH and its Affiliates; Expands Proprietary Offering for Diagnostic and Drug Discovery Workflows
April 12, 2021 |  finance.yahoo.com
Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
April 10, 2021 |  finance.yahoo.com
Molecular Partners AG: Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
Molecular Partners AG: Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
April 7, 2021 |  finanznachrichten.de
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
April 6, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MLLCF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.molecularpartners.com
Phone41 44 755 77 00
Employees145
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.46 out of 5 stars

Medical Sector

1684th out of 2,044 stocks

Biotechnology Industry

110th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Molecular Partners (OTCMKTS:MLLCF) Frequently Asked Questions

Is Molecular Partners a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Molecular Partners stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLLCF, but not buy additional shares or sell existing shares.
View analyst ratings for Molecular Partners or view top-rated stocks.

What stocks does MarketBeat like better than Molecular Partners?

Wall Street analysts have given Molecular Partners a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Molecular Partners wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Molecular Partners' key executives?

Molecular Partners' management team includes the following people:
  • Dr. Patrick Amstutz, Co-Founder, CEO, Member of Management Board & Director (Age 46, Pay $605.12k)
  • Dr. Michael Tobias Stumpp Ph.D., Co-Founder, COO & Member of Management Board (Age 49)
  • Mr. Andreas Emmenegger E.M.B.A., CFO & Member of Management Board (Age 55)
  • Dr. Nicolas Leupin M.B.A., M.D., MBA, Chief Medical Officer & Member of Management Board (Age 48)
  • Mr. Daniel Steiner Ph.D., Sr. VP of Research
  • Dr. Hans Kaspar Binz Ph.D., VP of Technology
  • Mr. Seth D. Lewis, Sr. VP of Investor Relations, Communications & Strategy
  • Mr. Julien Gander, Gen. Counsel, VP Legal & Sec. of the Board
  • Mr. Thomas Schwerzmann, VP of HR
  • Mr. Alexander Zürcher, Sr. VP of Devel.

Who are some of Molecular Partners' key competitors?

Some companies that are related to Molecular Partners include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of MLLCF's competitors.

What is Molecular Partners' stock symbol?

Molecular Partners trades on the OTCMKTS under the ticker symbol "MLLCF."

How do I buy shares of Molecular Partners?

Shares of MLLCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Partners' stock price today?

One share of MLLCF stock can currently be purchased for approximately $22.48.

How many employees does Molecular Partners have?

Molecular Partners employs 145 workers across the globe.

What is Molecular Partners' official website?

The official website for Molecular Partners is www.molecularpartners.com.

How can I contact Molecular Partners?

The company can be reached via phone at 41 44 755 77 00.


This page was last updated on 5/15/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.